Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Rhythm Pharmaceuticals Inc. (RYTM)

NASDAQ: RYTM · Pharmaceutical Preparations · Boston, MA

Our rating: Positive

Call changed from Cautious to Positive at $110.68, moderate conviction, November 4, 2026.

Breaks if: The Positive call breaks if reported revenue growth decelerates below 20% year-over-year in either of the next two quarterly filings — that pace would signal the commercial ramp is plateauing well short of what the 40x revenue multiple requires. It also breaks if annual free cash flow deteriorates to worse than -$175M in the next reported period, meaning the gap between accounting losses and actual cash outflows is narrowing in the wrong direction rather than compressing toward breakeven.

Key figures

Market value$7.8B
Revenue, last 12 months$281M
Net income, last 12 months−$194M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating margin−66.7%
Return on equity−163.7%
Beta to the S&P 5000.95
Volatility, annualized55.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$92M79.6%$-0.61n/a
June 30, 2026$71M46.9%$-0.73n/a
March 31, 2026$60M83.8%$-0.83n/a
December 31, 2025$57M36.9%$-0.73−$26M
September 30, 2025$51M54.3%$-0.82n/a
June 30, 2025$49M66.8%$-0.75n/a
March 31, 2025$33M25.9%$-0.81n/a
December 31, 2024$42M72.6%$-0.72n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 27 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.